NMN vs. NR: Which NAD+ Booster Actually Helps Your Eyes?

If you already take an NAD+ supplement, perhaps after reading the cellular-energy case for treating your eyes the way you treat your bones, you have probably run into this exact fork in the road. NMN or NR. Two different letters, two different molecules, and a genuinely confusing amount of marketing telling you each one is the superior choice. The debate got a fresh jolt in late 2025, when the FDA reversed a three-year-old ruling and confirmed that NMN is lawful to sell as a dietary supplement after previously excluding it. That reopened the comparison conversation across the entire longevity supplement world in 2026.

Almost all of that conversation is about general longevity. Almost none of it asks the more specific question you are actually here for: what does the eye-specific evidence show for each one? Your retina is one of the most energy-hungry tissues in your body, so if an NAD+ precursor is going to help anywhere, this is a reasonable place to look. Here is what the research actually says, molecule by molecule.

What Are NMN and NR, and How Are They Different?

NMN stands for nicotinamide mononucleotide. NR stands for nicotinamide riboside. Both are forms of vitamin B3, and both are precursors your body converts into NAD+, the molecule every cell in your body uses to turn food into usable energy. Think of NAD+ as the fuel that keeps the tiny power generators inside your cells running, and NMN and NR as two different delivery trucks carrying that fuel toward the same destination.

Here is where they differ. NR is one step further along the conversion pathway than NMN, and it uses its own dedicated route into your cells. According to PubMed, research on the enzyme BST1 shows that NR relies on a specific glycohydrolase and base-exchange pathway to enter cells efficiently, a route NMN does not use in the same way (Yaku K, et al. Nature Communications, 2021. PMID: 34799586. DOI: 10.1038/s41467-021-27080-3). In plain terms, NR has a more direct absorption route once it reaches your cells, part of the science of NAD+ and cellular energy in the eye that NADefense was built around. NMN, by contrast, generally needs to be broken down to NR first before your cells can use it. This is a mechanistic distinction, not a proven clinical advantage on its own, but it is the biological reason NR's absorption story is more straightforward.

Why Is This Comparison Everywhere Right Now?

In September 2025, the FDA sent letters concluding that NMN meets the legal definition of a dietary supplement, reversing a November 2022 determination that had excluded it because of its prior investigation as a drug. The reversal followed a multi-year challenge from the Natural Products Association, including a citizen petition and a federal lawsuit. That regulatory whiplash is exactly the kind of story that reopens a comparison conversation, and 2026 has seen a wave of new NMN-versus-NR content as a result.

Most of it treats this as a general anti-aging question. It rarely asks what either molecule has actually shown in a human eye. That is the gap this post is here to close.

What Does the Human Evidence Show for NMN?

According to PubMed, the most relevant human data for NMN comes from an 8-week, single-arm, open-label trial out of Keio University in Japan. Eleven healthy, middle-aged men took two 125 mg NMN capsules daily. The supplement was well tolerated, and NAD+ levels in their blood cells rose over the study period (Yamaguchi S, et al. Endocrine Journal, 2024;71(2):153-169. PMID: 38191197. DOI: 10.1507/endocrj.EJ23-0431).

Here is the honest limitation. The researchers did track ophthalmologic parameters as part of the safety monitoring, but the study did not report a distinct eye-health outcome or measure any change in visual function. This was an 11-person, 8-week safety and metabolism study, not an eye trial. It tells you NMN can raise NAD+ in humans. It does not tell you anything specific about what that means for your vision.

What Does the Human Evidence Show for NR, and for Nicotinamide?

For NR itself, the clearest human data is not eye-specific either, but it is more direct on the core mechanism. According to PubMed, a randomized, placebo-controlled crossover trial found that oral nicotinamide riboside raised NAD+ and lowered biomarkers of neurodegenerative pathology in blood-based extracellular vesicles of neuronal origin (Vreones M, et al. Aging Cell, 2023;22(1):e13754. DOI: 10.1111/acel.13754). That is a real human trial showing NR does what it is supposed to do inside the body. It is a neurological biomarker study, not a vision study, and it should be described as exactly that.

Now for the part that actually matters most for your eyes, with one careful distinction up front. Nicotinamide, the compound tested in the strongest eye-specific human trials below, is a related but chemically different form of vitamin B3 than nicotinamide riboside. Both feed into the same NAD+ pathway, but they are not the same molecule, and no clinical trial has tested NR by itself in human eyes. With that distinction stated plainly, here is why this research still matters to the NAD+-and-eyes conversation.

The Columbia Phase 2 Trial (2022)

Researchers at Columbia University Irving Medical Center ran a double-blind, placebo-controlled Phase 2 trial in 32 patients with treated open-angle glaucoma and moderate visual field loss. Participants received ascending doses of oral nicotinamide (up to 3,000 mg per day) and pyruvate (up to 3,000 mg per day) against placebo. The number of visual field test locations that improved beyond normal variability was significantly higher in the treatment group than placebo, a median of 15 locations versus 7 (P = .005) (De Moraes CG, John SWM, Williams PA, et al. JAMA Ophthalmology, 2022;140(1):11-18. PMID: 34792559. DOI: 10.1001/jamaophthalmol.2021.4576). No serious adverse events were reported. This was a small, short-term study, and the authors themselves called for longer trials to confirm the finding.

That call has already been answered. According to PubMed, a Phase III randomized controlled trial is now underway at Columbia and Stanford, testing 3 g per day of nicotinamide and 1 g per day of calcium pyruvate against placebo over 21 months in patients with open-angle glaucoma, on top of their standard intraocular pressure treatment. The trial's design and methodology were published in December 2025, with recruitment running from March 2023 through August 2025 (Shukla AG, Tsamis E, De Moraes CG, et al. Ophthalmology Glaucoma, 2025. PMID: 41461224. DOI: 10.1016/j.ogla.2025.12.008). Results are not yet available. This is a watch-this-space data point, not a finished answer, but it tells you the strongest eye-specific evidence for a B3-derived NAD+ precursor has moved from a 32-person pilot to a full Phase III trial in under four years. That kind of momentum does not happen with weak science.

So Which One Actually Has an Edge for Eye Health?

Here is where you pump the brakes and take the honest, full picture. Neither NMN nor NR, tested by itself, has a completed human trial measuring eye-specific outcomes. The molecule with real human eye-specific evidence behind it is nicotinamide, a related but distinct B3 precursor now advancing through Phase III glaucoma trials. NR's case for your eyes rests on two separate pillars: a more efficient, well-characterized cellular absorption pathway, and its position in the same NAD+ biosynthesis pathway that the nicotinamide glaucoma research is built on.

NMN's case is thinner by comparison. Its human safety data is real, but it comes from a small metabolic study that never specifically evaluated eye outcomes, and its own absorption story runs through conversion to NR before your cells can use it. Given the choice between the two, and consistent with what fifteen years of screens really asks of your retina's cellular energy demand, NR is the more mechanistically direct and better-substantiated pick for anyone specifically thinking about their eyes, even though the strongest clinical proof point in this space belongs to a related molecule, not either one by name.

What Does This Mean for You?

If you are choosing between NMN and NR with your eyes specifically in mind, here is the practical takeaway. NR has the more direct absorption pathway and sits closer, mechanistically, to the B3-derived NAD+ precursor research that has produced real human eye data, even though that specific trial used nicotinamide rather than NR itself. NMN's human evidence is real but general, not eye-specific, and its own path to NAD+ runs through NR.

This is not a reason to stop anything your doctor has you doing for eye pressure or disease management. Standard glaucoma care, and regular eye exams, remain the foundation. NAD+ precursors are being studied as an additional layer of cellular support, not a replacement for that care.

For people who already think in terms of cellular energy and longevity, Sight Guard was formulated around this same research. It uses nicotinamide riboside, at 300 mg, specifically because of its more direct absorption pathway, alongside calcium pyruvate, the same compound studied alongside nicotinamide in the glaucoma trials above. Sight Guard is designed to support cellular energy and optic nerve health as part of a proactive, long-term routine, not as a treatment for any eye disease.

Bigger Picture

The NMN-versus-NR debate is really a proxy for a bigger question: which NAD+ precursor has the clearest path from cell biology to a real human benefit. For general longevity, that question is still open. For the eye specifically, the answer is becoming clearer faster than most people realize. A 32-person pilot trial in glaucoma patients has already grown into a Phase III study at two major academic centers in under four years. Whichever molecule you choose, that is the research trajectory worth watching.

References

1. Yaku K, Palikhe S, Izumi H, et al. BST1 regulates nicotinamide riboside metabolism via its glycohydrolase and base-exchange activities. Nature Communications. 2021;12(1):6767. PMID: 34799586. DOI: 10.1038/s41467-021-27080-3.

2. Yamaguchi S, Irie J, Mitsuishi M, et al. Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men. Endocrine Journal. 2024;71(2):153-169. PMID: 38191197. DOI: 10.1507/endocrj.EJ23-0431.

3. Vreones M, Mustapic M, Moaddel R, et al. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754. DOI: 10.1111/acel.13754.

4. De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial. JAMA Ophthalmology. 2022;140(1):11-18. PMID: 34792559. DOI: 10.1001/jamaophthalmol.2021.4576.

5. Shukla AG, Tsamis E, De Moraes CG, et al. Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection, Design and Methodology. Ophthalmology Glaucoma. 2025. PMID: 41461224. DOI: 10.1016/j.ogla.2025.12.008.

6. Venable LLP. FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement. October 2025. https://www.venable.com/insights/publications/2025/10/fda-declares-nicotinamide-mononucleotide-is